All News

renal.genes_.jpg

Iberdomide in Systemic Lupus Erythematosus

Jack Cush, MD

The NEJM reports that systemic lupus erythematosus (SLE) patients treated with iberdomide, a cereblon modulator, was effective at yielding a significant SRI-4 clinical response after 24 weeks. 

Read Article
pollution,smoke

Environmental Pollutants Ups Autoimmune Disease Risk

Jack Cush, MD

An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).

Read Article
RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
lupus,nephritis,GN

Could Anifrolumab Work in Lupus Nephritis?

Jack Cush, MD

Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.

Read Article
Lupus,flare,malar,DermNetNZ

Increased SLE Flares with Hydroxychloroquine Reduction

Jack Cush, MD

Concerns about the long-term safety of hydroxychloroquine (HCQ) often results in dose reduction or drug discontinuation; yet a current study shows that, for those in remission, HCQ taper/discontinuation resulted in a significantly higher rate of SLE flares.

Read Article
RheumNow Podcast square

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.

Read Article
SLE,malar,black

ACR Addresses Racial Disparities in Lupus Trials

ACR

The American College of Rheumatology (ACR) is launching two new initiatives to reduce racial disparities in lupus clinical trials: Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) and new Continuing Medical Educatio

Read Article
Remarkable heterogeneity in results of #ANA testing using different assays #PeterLipsky on “Almighty ANA” at #RNL2022 @RheumNow https://t.co/A0y3ugBBrz
Elena MyasoedovaMD MyasoedovaElena ( View Tweet)
ANA levels fluctuate & depend on the https://t.co/rjZhNvSzE1 should we use it as an entry criterion to diagnose lupus ? #RNL2022

Links:

madan madanpadmajan1 ( View Tweet)

ANA in otherwise healthy: Anti-DFS70 antibodies (Dense Fine Speckled, 70kDa molecular weight) are a sub-group of anti-nuclear antibodies. Peter Lipsky @rhumnow #Rnl2022 https://t.co/QH4qsdzZmu
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Q and A Positive ANA post COVID infection and vaccination? ⬇️ 1- Repeat test ( transient elevation). 2-Monitor clinical symptoms. PS, COVID infection ▶️lupus anti coagulant and catastrophic APS like syndrome. @RheumNow #Rnl2022

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

ANA variability among different platforms and essays. Validated quantification test are needed!! Peter Lipsky @rhumnow #rnl2022 https://t.co/pyJhBkJE8P
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
RheumNow Live is Coming to Town! Have you signed up for RheumNow Live yet? We still have space available. https://t.co/FBCQRu32gO https://t.co/KoGR8An6af https://t.co/qtwPbMzqSO

Links:

Dr. John Cush RheumNow ( View Tweet)
Could Anifrolumab Work in Lupus Nephritis? Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit. https://t.co/6EtLf1nhv6 https://t.co/RrJX08vcIK

Links:

Dr. John Cush RheumNow ( View Tweet)
New Download Available! Autoimmune Disease in the USA https://t.co/KvsgBUY7mL https://t.co/PSTF7ma6G6

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Increased SLE Flares with HCQ Reduction Concerns about the long-term safety of HCQ often results in dose reduction or drug discontinuation; study shows that, for those in remission, HCQ taper/discontinuation resulted in a higher rate of SLE flares. https://t.co/l0Xh1oQzQA https://t.co/HyDbqKrEFp

Links:

Dr. John Cush RheumNow ( View Tweet)
2/28, was “Rare Disease Day” in the USA, w/many tributes to the patients, doctors & researchers dedicated to these disorders. Moreover, it was a great opportunity to shout about the many rare conditions that don’t get enough press, praise or funding. https://t.co/ft8Y8Mmdnz https://t.co/WqhRGzNRtS

Links:

Dr. John Cush RheumNow ( View Tweet)
Listen in… Fellow Case Presentations From RWCS 2022 https://t.co/SvaGfyDDTK https://t.co/MP9iWQK8ZB

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: 144 SLE pts from the SLICC cohort were studied showing that a majority (61.2%) scores consistent with depression over 4 yrs; also an inconsistent association between disease activity and depression in multivariate analysis https://t.co/YqxPFtYohf

Links:

Dr. John Cush RheumNow ( View Tweet)

SLE mortality rates (ASMR) nearly doubled since 1998 & remain high (vs non-SLE mortality) w/ significant sex & regional disparities. Data from 11449 SLE deaths, ASMR signif increased 1998 to 2009, down 2009 to 2013 and increased thereafter https://t.co/kSc3Cn2Bl5

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×